Genscript Biotech's Long-Term Growth Logic Looks Clear -- Market Talk

Dow Jones08-13

0750 GMT - Genscript Biotech's long-term growth logic looks clear, Ethan Ding, equity analyst at Bocom International writes in a note. Its core business is growing firmly, with its new business gaining momentum, and new customers rising 5.4% in 1H, Ding highlights. Its life science services and products segment's revenue rose 10%, and though the segment faced temporary fluctuations in the U.S. market in June, it resumed growth in July, Ding adds. Capacities in China and the U.S. are also expected to continue expanding in 2024-2026, and technological innovation will be a long-term driver for growth, Ding adds. Bocom retains its buy rating, raising the target price to HK$28.75 from HK$27.75. Shares are 2.6% higher at HK$13.24. (kimberley.kao@wsj.com)

(END) Dow Jones Newswires

August 13, 2024 03:50 ET (07:50 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2459940629?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-13 15:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2459940629","market":"sg","top_or_hot":-1,"title":"Genscript Biotech's Long-Term Growth Logic Looks Clear -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0750 GMT - Genscript Biotech's long-term growth logic looks clear, Ethan Ding, equity analyst at Bocom International writes in a note. Its core business is growing firmly, with its new business gaining momentum, and new customers rising 5.4% in 1H, Ding highlights. Its life science services and products segment's revenue rose 10%, and though the segment faced temporary fluctuations in the U.S. market in June, it resumed growth in July, Ding adds. Capacities in China and the U.S. are also expected to continue expanding in 2024-2026, and technological innovation will be a long-term driver for growth, Ding adds. Bocom retains its buy rating, raising the target price to HK$28.75 from HK$27.75. Shares are 2.6% higher at HK$13.24. (kimberley.kao@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 13, 2024 03:50 ET (07:50 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genscript Biotech's Long-Term Growth Logic Looks Clear -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenscript Biotech's Long-Term Growth Logic Looks Clear -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-13 15:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>0750 GMT - Genscript Biotech's long-term growth logic looks clear, Ethan Ding, equity analyst at Bocom International writes in a note. Its core business is growing firmly, with its new business ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000320264.USD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2459940629","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2459940629","pubTimestamp":1723535400,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0750 GMT - Genscript Biotech's long-term growth logic looks clear, Ethan Ding, equity analyst at Bocom International writes in a note. Its core business is growing firmly, with its new business gaining momentum, and new customers rising 5.4% in 1H, Ding highlights. Its life science services and products segment's revenue rose 10%, and though the segment faced temporary fluctuations in the U.S. market in June, it resumed growth in July, Ding adds. Capacities in China and the U.S. are also expected to continue expanding in 2024-2026, and technological innovation will be a long-term driver for growth, Ding adds. Bocom retains its buy rating, raising the target price to HK$28.75 from HK$27.75. Shares are 2.6% higher at HK$13.24. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","BK1576":"医药外包概念","BK1141":"生命科学工具和服务","01548":"金斯瑞生物科技","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK1583":"高瓴概念"},"translate_title":"金斯瑞生物长期增长逻辑清晰--市场谈","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":0.9},"content_text":"0750 GMT - Genscript Biotech's long-term growth logic looks clear, Ethan Ding, equity analyst at Bocom International writes in a note. Its core business is growing firmly, with its new business gaining momentum, and new customers rising 5.4% in 1H, Ding highlights. Its life science services and products segment's revenue rose 10%, and though the segment faced temporary fluctuations in the U.S. market in June, it resumed growth in July, Ding adds. Capacities in China and the U.S. are also expected to continue expanding in 2024-2026, and technological innovation will be a long-term driver for growth, Ding adds. Bocom retains its buy rating, raising the target price to HK$28.75 from HK$27.75. Shares are 2.6% higher at HK$13.24. (kimberley.kao@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 13, 2024 03:50 ET (07:50 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2459940629"}